The UB becomes a shareholder of Reveal Genomics, a spin-off born to develop innovative diagnostic tests in oncology

Aleix Prat (Hospital Clínic-UB) and Patricia Villagrasa-González (Reveal Genomic

Aleix Prat (Hospital Clínic-UB) and Patricia Villagrasa-González (Reveal Genomics).

The University of Barcelona has become a shareholder of Reveal Genomics, a spin-off of Hospital Clínic and Vall d’Hebron Institute of Oncology (VHIO), which plans to develop and market precision diagnostic tools in oncology based on he combination of different genomic data. First, the spin-off will focus on the improvement of breast cancer diagnosis with tools that enable them to personalize the treatment of the disease.


This site uses cookies and analysis tools to improve the usability of the site. More information. |